10-[(1-甲基-3-哌啶基)甲基]-10H-吩噻嗪单乙酸盐 | 24360-97-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 10-[(1-甲基-3-哌啶基)甲基]-10H-吩噻嗪单乙酸盐
• 中文别名: 1,2-吡咯烷二羧酸,1-甲基酯,(2S)-
• 英文名称: 10-[(1-Methylpiperidin-1-ium-3-yl)methyl]phenothiazine;acetate
• CAS: 24360-97-2
• 化学式: C21H26N2O2S
• 分子量: 370.5
• InChiKey: COBIOCPXKOZHSU-UHFFFAOYSA-N

物化性质

• 溶解度：
  >55.6 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  4.72
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934300000

文献信息

• [EN] INHIBITORS OF MALT1 PROTEASE<br/>[FR] INHIBITEURS DE LA PROTÉASE MALT1
  申请人：HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH

  公开号：WO2014086478A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds which are inhibitors of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALTl) and to their use in therapy, in particular in the treatment or prevention of a disease or disorder which is treatable by an inhibitor of a paracaspase. The present invention also relates to pharmaceutical compositions containing such compounds.

  本发明涉及作为粘膜相关淋巴组织淋巴瘤易位蛋白1（MALT1）抑制剂的化合物及其在治疗中的应用，尤其是在治疗或预防可通过抑制paracaspase治疗的疾病或失调中的应用。本发明还涉及含有该化合物的药物组合物。
• PHENOTHIAZINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH

  公开号：EP3473254A1

  公开（公告）日：2019-04-24

  The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) wherein X is N or C; Y is S, O, SO2, SO, NH, CO, CH2, CH=CH, or CH2-CH2; ()z is a C1-C5 linear or branched alkyl chain; A is NR3R4, or OR5, or HET; R1 and R2 in each occurrence are independently selected from -H, -CH3, -OH, -OCH3, -SCH3, -F, -CI, -CF3, -NH2, and-COOH; R3, R4, and R5 are H, or C1-C5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C1-C5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1-dependent immune diseases

  本发明涉及一种用于治疗癌症的化合物，其中癌症依赖于 MALT1 蛋白酶的蛋白分解活性，且该化合物具有通式 (I) 其中 X 是 N 或 C；Y 是 S、O、SO2、SO、NH、CO、CH2、CH=CH 或 - ；()z 是 C1-C5 直链或支链烷基链；A 是 NR3R4、或 OR5、或 HET；每次出现的 R1 和 R2 独立选自-H、-CH3、-OH、-O 、-S 、-F、-CI、-CF3、-NH2 和-COOH；R3、R4 和 R5 是 H 或 C1-C5 直链或支链烷基，HET 是由 5、6 或 7 个成员组成的杂环，其中环原子可以是 C、O、N 或 S，环可以是饱和或芳香的，环可以被 H 或 C1-C5 直链或支链烷基取代；或所述化合物的药学上可接受的盐、原药、对映体、非对映体、外消旋混合物、结晶形式、无定形形式、未溶形式或溶解物。本发明的化合物可进一步用于治疗 MALT1 依赖性免疫疾病
• SELECTIVE INHIBITION OF MALT1 PROTEASE BY PHENOTHIAZINE DERIVATIVES
  申请人：Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

  公开号：EP2739285A1

  公开（公告）日：2014-06-11
• Methods and compositions for screening and treatment of disorders of blood glucose regulation
  申请人：McCamish Mark A.

  公开号：US20080280955A1

  公开（公告）日：2008-11-13

  In one aspect, the invention provides a method of screening and, optionally, treatment of an individual suffering from an insulin resistance disorder by screening an individual in need of treatment for an insulin resistance disorder for one or more genetic variations indicating a predisposition to a response to an insulin sensitizer; and, optionally, administering or not administering an insulin sensitizer to the individual based on the results of the screening. The insulin sensitizer for which the individual is screened and the insulin sensitizer that is administered or not administered may be the same or different. In another aspect, the invention provides methods comprising identifying one or more genetic variations, e.g., one or more single nucleotide polymorphisms, that at least partly differentiate between a subset of a plurality of individuals who experience a response when administered an insulin sensitizer, and a subset of said plurality of individuals who do not experience a response when administered the insulin sensitizer. The invention also provides nucleic acids, polypeptides, antibodies, kits, and business methods associated with these screening and association methods.
• Selective inhibition of MALT1 protease by phenothiazine derivatives
  申请人：Krappmann Daniel

  公开号：US20140288060A1

  公开（公告）日：2014-09-25

  The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) wherein X is N or C; Y is S, O, SO 2 , SO, NH, CO, CH 2 , CH═CH, CH 2 ═CH 2 ; ( ) z is a C 1 -C 5 linear or branched alkyl chain; A is NR 3 R 4 , or OR 5 , or HET; R 1 and R 2 in each occurrence are independently selected from —H, —CH 3 , —OH, —OCH 3 , —SCH 3 , —F, —Cl, —CF 3 , —NH 2 , and —COOH; R 3 , R 4 , and R 5 are H, or C 1 -C 5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C 1 -C 5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1-dependent immune diseases.